|1.||Kim, Sung-Hoon: 11 articles (02/2014 - 01/2006)|
|2.||Lee, Hyo-Jung: 6 articles (01/2013 - 01/2006)|
|3.||Jeong, Soo-Jin: 4 articles (02/2014 - 01/2010)|
|4.||Jiang, Cheng: 4 articles (12/2012 - 01/2006)|
|5.||Song, Gyu-Yong: 4 articles (01/2012 - 12/2007)|
|6.||Lee, Hyo-Jeong: 4 articles (12/2010 - 01/2006)|
|7.||Kim, Ik-Hwan: 3 articles (11/2014 - 06/2005)|
|8.||Han, Hogyu: 3 articles (11/2014 - 06/2005)|
|9.||Chae, Jung-Woo: 3 articles (11/2014 - 10/2011)|
|10.||Suh, Hong-Won: 3 articles (01/2013 - 06/2003)|
|1.||Breast Neoplasms (Breast Cancer)
01/01/2007 - "These data provide mechanistic rationales for validating the chemopreventive and therapeutic efficacy of decursin and its derivatives in preclinical animal models of breast cancer."
05/01/2014 - "However, the effect of decursin on breast cancer invasion is unknown. "
01/01/2007 - "The side chain of decursin and DA is crucial for their anti-ER signaling and breast cancer growth inhibitory activities. "
02/01/2014 - "Overall, our current study suggests the potential of decursin as an attractive cancer therapeutic agent for breast cancer by targeting Pin1 protein."
02/01/2014 - "This study demonstrates that decursin, a bioactive compound from Angelica gigas, exert the anti-cancer effect against breast cancer cells via regulation of Pin1 and its related signaling molecules. "
|2.||Colonic Neoplasms (Colon Cancer)
04/01/2010 - "Thus, these findings suggest that decursin has potential therapeutic efficacy for the treatment of bladder and colon cancer."
04/01/2010 - "In the present study, we found that decursin inhibited cell viability in cultured human urinary bladder cancer 235J cells and colon cancer HCT116 cells. "
04/01/2010 - "Decursin inhibits growth of human bladder and colon cancer cells via apoptosis, G1-phase cell cycle arrest and extracellular signal-regulated kinase activation."
12/01/2012 - "The in vitro anti-tumor activities of decursin and/or DA against prostate cancer, lung cancer, breast cancer, colon cancer, bladder cancer, sarcoma, myeloma and leukemia have been increasingly reported in the past decade whereas the in vivo efficacy in mouse models was established only for a few organ sites. "
|3.||Transient Ischemic Attack
10/01/2012 - "Protective effects of a novel synthetic α-lipoic acid-decursinol hybrid compound in experimentally induced transient cerebral ischemia."
10/01/2012 - "In this study, we synthesized a novel synthetic alpha-lipoic acid-decursinol (ALA-DA) hybrid compound, and compared neuroprotective effects of ALA, DA or ALA-DA against ischemic damage in the gerbil hippocampal CA1 region induced by 5 min of transient cerebral ischemia. "
02/01/2005 - "These findings suggest the novel anticancer efficacy of decursin mediated via induction of cell cycle arrest and apoptosis selectively in human prostate carcinoma cells."
05/01/2014 - "Decursin prevents TPA-induced invasion through suppression of PKCα/p38/NF-κB-dependent MMP-9 expression in MCF-7 human breast carcinoma cells."
02/01/2005 - "Here, for the first time, we observed that decursin (25-100 micromol/L) treatment for 24 to 96 hours strongly inhibits growth and induces death in human prostate carcinoma DU145, PC-3, and LNCaP cells. "
02/01/2005 - "A novel anticancer agent, decursin, induces G1 arrest and apoptosis in human prostate carcinoma cells."
07/01/2011 - "Decursin and decursinol inhibited the proliferation and invasion of CT-26 colon carcinoma cells. "
04/01/2008 - "These results suggest that decursinol could be effective for prevention or treatment of sepsis."
04/01/2008 - "The effects of decursinol on various models of sepsis were investigated. "
04/01/2008 - "Protective effect of decursinol on mouse models of sepsis: enhancement of interleukin-10."
04/01/2008 - "Intra-peritoneal pretreatment of mice with various doses of decursinol (1~100 mg/kg) effectively suppressed lethality induced in three mouse models of experimental sepsis, i.e., lipopolysaccharide (LPS)/D-galactosamine (GalN), high-dose LPS (20 mg/kg), and cecal ligation and puncture (CLP). "
|1.||Thioctic Acid (Lipoic Acid)
|3.||acrylic acid (acrylate)
|7.||Kainic Acid (Kainate)
|10.||Vascular Endothelial Growth Factor Receptor-2 (Vascular Endothelial Growth Factor Receptor 2)
|1.||Heterologous Transplantation (Xenotransplantation)
|4.||Homologous Transplantation (Allograft)
|5.||Traditional Medicine (Folk Remedies)